VANCOUVER, BRITISH COLUMBIA--(Marketwire - Oct. 25, 2011) -[ Allon Therapeutics Inc. ] (TSX:NPC) President and CEO, [ Gordon McCauley ], will present an update of the Company's business progress on Wednesday, October 26 at the [ 10th Annual BIO Investor Forum ] in San Francisco attended by public and private equity investors, research analysts, investment bankers, and the pharma community.

McCauley's presentation will include an update of the Company's programs, including its fully enrolled pivotal phase 2/3 clinical trial evaluating lead neuroprotective drug candidate, [ davunetide ], as a potential treatment for [ progressive supranuclear palsy ] (PSP), a rapidly progressing and fatal degenerative brain disease.

The live webcast may be viewed at 9:00 a.m. PDT (12:00 p.m. EDT) at [ http://www.veracast.com/webcasts/bio/investorforum2011/36202463.cfm ]

The presentation will be immediately archived and available for viewing for three months from the Company's website at [ www.allontherapeutics.com/corporate/news/events-and-webcasts/ ]

About BIO Investor Forum

The BIO Investor Forum is sponsored by the Biotechnology Industry Organization, the world's largest organization representing the biotech industry. The forum is exploring investment trends and opportunities in life sciences, with a focus on public and venture-stage growth companies as well as those poised to join the growth "watch list" for 2012.

About Allon

Allon Therapeutics Inc. is a clinical-stage biotechnology company focused on bringing to market innovative central nervous system therapies. Allon's lead drug davunetide is proceeding in a pivotal Phase 2/3 clinical trial in an orphan indication, progressive supranuclear palsy (PSP), under a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA). This pivotal trial is based upon statistically significant human efficacy demonstrated in patients with amnestic mild cognitive impairment (a precursor to Alzheimer's disease) and cognitive impairment associated with schizophrenia, and in positive biomarker data.

The Company is listed on the Toronto Stock Exchange under the trading symbol "NPC".

Forward Looking Statements

Statements contained herein, other than those which are strictly statements of historical fact may include forward-looking information. Such statements will typically contain words such as "believes", "may", "plans", "will", "estimate", "continue", "anticipates", "intends", "expects", and similar expressions. While forward-looking statements represent management's outlook based on assumptions that management believes are reasonable, forward-looking statements by their nature are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by them. Such factors include, among others, the inherent uncertainty involved in scientific research and drug development, Allon's early stage of development, lack of product revenues, its additional capital requirements, the risks associated with successful completion of clinical trials and the long lead-times and high costs associated with obtaining regulatory approval to market any product which Allon may eventually develop. Other risk factors include the limited protections afforded by intellectual property rights, rapid technology and product obsolescence in a highly competitive environment and Allon's dependence on collaborative partners and contract research organizations. These factors can be reviewed in Allon's public filings at [ www.sedar.com ] and should be considered carefully. Readers are cautioned not to place undue reliance on such forward-looking statements. Similarly, nothing in this press release is meant to promote a pharmaceutical product or make a regulated claim of efficacy.

Contributing Sources

---

Market Wire